VAIA
KRYS icon

Virtus Alternative Investment Advisers’s Krystal Biotech KRYS Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-130
Closed -$8K – 117
2020
Q4 		$8K Sell
130
-125
-49% -$6.24K 0.12% 77
2020
Q3 		$11K Sell
255
-35
-12% -$1.52K 0.2% 160
2020
Q2 		$12K Buy
+290
New +$14K 0.19% 237

Other funds holding KRYS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Virtus Alternative Investment Advisers's KRYS Position: Q1 2021 in Review

Virtus Alternative Investment Advisers sold out of Krystal Biotech (KRYS) in Q1 2021, closing a stake of 130 shares — an estimated $8K sold.

Virtus Alternative Investment Advisers first reported a position in KRYS in Q2 2020 and held it in 3 quarters. The position peaked at $12K in Q2 2020. 113 funds tracked by Wall St. Rank hold KRYS as of Q1 2021.

  • Virtus Alternative Investment Advisers reported no remaining Krystal Biotech position as of Q1 2021 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 130 Krystal Biotech shares in Q1 2021, an estimated $8K.
  • Virtus Alternative Investment Advisers first reported a position in Krystal Biotech in Q2 2020 and held it in 3 quarters.
  • Virtus Alternative Investment Advisers's Krystal Biotech position peaked at $12K in Q2 2020.
  • 113 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2021.

Based on Virtus Alternative Investment Advisers's 13F filing for Q1 2021.